These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Assessing the consistency of traditional Chinese medicine with multiple correlative active components. Lu Q; Chow SC; Tse SK J Biopharm Stat; 2007; 17(5):791-808. PubMed ID: 17885866 [TBL] [Abstract][Full Text] [Related]
4. Estimation of the shelf-life of drugs with mixed effects models. Chen JJ; Hwang JS; Tsong Y J Biopharm Stat; 1995 Mar; 5(1):131-40. PubMed ID: 7613558 [TBL] [Abstract][Full Text] [Related]
5. Stability of active ingredients of traditional Chinese medicine (TCM). Meng W; Xiaoliang R; Xiumei G; Vincieri FF; Bilia AR Nat Prod Commun; 2009 Dec; 4(12):1761-76. PubMed ID: 20120121 [TBL] [Abstract][Full Text] [Related]
6. United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: progress and promise. Khan SR; Kona R; Faustino PJ; Gupta A; Taylor JS; Porter DA; Khan M J Pharm Sci; 2014 May; 103(5):1331-6. PubMed ID: 24623105 [TBL] [Abstract][Full Text] [Related]
7. Estimating drug shelf-life with random batches. Chow SC; Shao J Biometrics; 1991 Sep; 47(3):1071-9. PubMed ID: 1742431 [TBL] [Abstract][Full Text] [Related]
8. WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445 [TBL] [Abstract][Full Text] [Related]
9. The concept of drug expiration dating. Wollish EG Bull Parenter Drug Assoc; 1969; 23(1):48-52. PubMed ID: 5765721 [No Abstract] [Full Text] [Related]
10. Evaluating the performance of the ICH guidelines for shelf life estimation. Quinlan M; Stroup W; Schwenke J; Christopher D J Biopharm Stat; 2013; 23(4):881-96. PubMed ID: 23786363 [TBL] [Abstract][Full Text] [Related]
11. International Conference on Harmonisation; evaluation of stability data; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2004 Jun; 69(110):32010-1. PubMed ID: 15185712 [TBL] [Abstract][Full Text] [Related]
13. Pooling data for stability studies: testing the equality of batch degradation slopes. Ruberg SJ; Stegeman JW Biometrics; 1991 Sep; 47(3):1059-69. PubMed ID: 1742430 [TBL] [Abstract][Full Text] [Related]
14. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
15. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety. Woo J; Wolfgang S; Batista H Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142 [TBL] [Abstract][Full Text] [Related]
16. Regulatory, design, and analysis aspects of complex stability studies. US Food & Drug Administration. Fairweather WR; Lin TY; Kelly R J Pharm Sci; 1995 Nov; 84(11):1322-6. PubMed ID: 8587050 [TBL] [Abstract][Full Text] [Related]
17. stab: an R package for drug stability data analysis. Lee HY; Wu PC; Lee YJ Comput Methods Programs Biomed; 2010 Nov; 100(2):140-8. PubMed ID: 20363045 [TBL] [Abstract][Full Text] [Related]
18. Sterility requirement for aqueous-based drug products for oral inhalation. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 May; 65(103):34082-9. PubMed ID: 11010719 [TBL] [Abstract][Full Text] [Related]
19. The role of degradant profiling in active pharmaceutical ingredients and drug products. Alsante KM; Ando A; Brown R; Ensing J; Hatajik TD; Kong W; Tsuda Y Adv Drug Deliv Rev; 2007 Jan; 59(1):29-37. PubMed ID: 17187892 [TBL] [Abstract][Full Text] [Related]
20. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. Paulekuhn GS; Dressman JB; Saal C J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]